FDAnews Drug Daily Bulletin

CERAGENIX COMPLETES $3.2 MILLION CONVERTIBLE NOTE TRANSACTION

Dec. 7, 2005
A A

Ceragenix Pharmaceuticals, Inc., ("Ceragenix" or the "Company"), a development stage biopharmaceutical company, (OTCBB:CGXP) today announced that it had completed a financing in which the Company sold $3.2 million in convertible notes (the "Notes") in a private transaction to four institutional investors. The Notes accrue interest at the rate of 10% per annum, payable quarterly, with principal and any accrued interest payable in full on November 28, 2007.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051206005287&newsLang=en)